U-100 Insulin Syringes Explained for Healthcare Buyers

1. U-100 Is a Scale Identity, Not a Complete Product Description

On an insulin vial, U-100 identifies a concentration of 100 insulin units per milliliter. On an empty insulin syringe, it identifies the matching unit scale; the syringe does not contain insulin simply because it is labeled U-100. The HUMULIN R prescribing information is one product-label example that identifies the medicine as 100 units/mL (U-100).^[7]

Read the scale before the rest of the order line. A familiar cap color, a clear photograph or a matching needle size cannot replace the U-100 marking and manufacturer reference on the approved product.

Procurement rule: Treat “U-100” as a non-substitutable product-identity field. Confirm it before capacity, needle size, packaging or price enters the comparison.

2. What U-100 Does—and Does Not—Tell a Buyer

3. Is a U-100 Insulin Syringe Always 1 mL?

No. U-100 describes the concentration scale, while milliliters describe physical barrel capacity. The following table is a category-level purchasing snapshot, not a statement that every manufacturer’s markings, needle choices or package counts are identical.

For a fuller comparison of barrel sizes, unit capacities, gauge and needle length, use Tonmit’s guide to compare 0.3 mL, 0.5 mL and 1 mL insulin syringe sizes. This article intentionally keeps the size discussion short so the U-100 page remains focused on identity and procurement control.

4. How to Decode a Complete U-100 Insulin Syringe SKU

Start with the requested device, not the shortest catalog description. A usable quotation line looks like this:

This is an example of the fields to collect, not a Tonmit SKU specification. Replace the bracketed entries with the supplier’s documents. Keep the request, offered product and received product in separate columns so that a difference remains visible. Our wholesale insulin syringe page is the next step for configuration and supply review.

5. Why Graduation Must Be Verified by Exact REF

Capacity and graduation answer different questions. Capacity establishes how much the barrel can contain; graduation establishes what the interval between adjacent scale lines represents. A catalog may contain several U-100 products that share capacity but differ in graduation, needle dimensions or safety configuration.

The BD SafetyGlide overview gives a useful, specific example: catalog number 328449 is listed as a 0.3 mL, 31G × 6 mm syringe with half-unit markings. The same overview lists other barrel capacities under different catalog numbers.^[1] This shows how to verify a graduation claim by reference; it is not evidence that every 0.3 mL syringe, or a Tonmit product, has those markings.

Do not state “all 1 mL U-100 syringes use two-unit graduations” or “all 0.3 mL syringes use half-unit markings.” Those claims are too broad for SKU-controlled procurement.

6. U-100 vs U-40 and U-500: Prevent Cross-Concentration Substitution

U-40, U-100 and U-500 identify different concentration systems. Similar needle dimensions do not make their administration devices interchangeable. The current HUMULIN R U-500 prescribing information, revised July 2026, describes a prefilled KwikPen and explicitly prohibits transferring insulin from that pen into any syringe.^[2] A historical syringe announcement is not a substitute for checking today’s labeled presentation.

For procurement, confirm the medicine presentation and the device specified by its current labeling. Do not solve a shortage by changing concentration scales or drawing from a pen with a U-100 syringe. The U-40 versus U-100 guide covers the separate inventory controls; this page does not provide conversion instructions.

7. Fixed-Needle, Safety and Luer Configurations Are Separate Decisions

“U-100” does not establish how the needle or connection is configured. Many familiar retail insulin syringes use an attached fixed needle, but safety insulin syringes have an actual protective mechanism and Luer configurations serve different connection and use pathways. A standard fixed-needle product must not be marketed as a safety syringe simply because it has a needle cap.

A documented example is Cardinal Health’s September 2024 recall communication for certain Monoject U-100 1 mL Luer-Lock syringe lots. The FDA notice concerns incompatibility with needleless IV connectors.^[3] The purchasing lesson is limited but useful: the configuration, product code and lot matter. This is not a recall of all U-100 syringes or of Tonmit fixed-needle products.

8. Put U-100 Into Catalog, PO and Warehouse Controls

U-100 should be visible wherever staff make a selection, substitution, receiving or traceability decision. Hiding the scale in a long description while the short title reads only “insulin syringe 31G” creates avoidable ambiguity.

U-100 INSULIN SYRINGE RECEIVING AND EXCEPTION RECORD
Blank buyer worksheet - one record per REF / lot combination

RECEIPT
Purchase order / delivery reference:
Date received:
Storage location:
Receiver:

APPROVED PRODUCT
Legal manufacturer / labeler:
Manufacturer REF / buyer SKU:
Scale: U-100
Barrel capacity / maximum unit marking:
Smallest printed graduation:
Gauge x needle length:
Fixed needle / safety / other approved configuration:
Approved label or specification revision:
Primary pack / pieces per box / boxes per case:
Minimum remaining shelf life:

RECEIVED PRODUCT - RECORD THE LABEL, NOT THE ASSUMPTION
Manufacturer / labeler:
REF / buyer SKU:
Scale / capacity / maximum marking:
Graduation / gauge x length / configuration:
Label or packaging revision:
UDI / GTIN and package level, where applicable:
Lot / batch:
Expiry:
Quantity received (state pieces, boxes or cases):
Primary pack and box/case counts:
Visible sterile-barrier or shipping damage:
Evidence / photograph reference (no patient identifiers):

EXCEPTION REVIEW
Difference from approved product:
Affected quantity and stock location:
Action: HOLD / QUARANTINE / RELEASE / REJECT / AUTHORIZED CHANGE
Responsible reviewer / date:
Written approval or corrective-action reference:
Final accepted quantity:

METHOD AND LIMITS
Compare order/specification records with the received label, packaging and visible condition.
Follow the site's approved sampling and release procedure; do not open sterile barriers merely
for visual comparison. This blank worksheet is not a completed Tonmit QC record, laboratory
test, regulatory certificate, proof of sterility or a patient-specific selection tool.

9. Verify U-100 Product Claims With Evidence, Not Catalog Language

Ask for the document that resolves the open question. A barrel drawing helps verify graduation; a carton label helps verify pack count; a lot-specific response helps verify dating. Request product documentation for the offered REF, rather than a folder of certificates that may describe another device.

10. Box, Case, Shelf-Life and Landed-Cost Controls

“100 syringes per box” does not establish how many boxes are in a case, whether units are bagged or individually presented, or how freight should be compared. Record each packaging level and calculate commercial terms against the accepted-syringe count.

Total landed program cost can include product, packaging, freight, duty, brokerage, warehousing, domestic delivery, inspection, rejected goods, shortage management and administrative work. Use the guide to calculate insulin syringe case quantities and landed cost after locking the exact U-100 SKU.

Private-label programs introduce additional artwork, identifier, role and change-control questions. Buyers considering branded packaging should separately review private-label insulin syringe requirements rather than treating a logo change as a purely graphic task.

11. Regulatory and Quality Documentation Must Match the Exact Product

FDA states that it does not issue registration certificates to medical-device facilities and that registration and listing do not by themselves denote approval, clearance or authorization.^[4] For U.S. procurement, a screenshot headed “FDA registered” is therefore not a complete product review.

For example, FDA’s FMF classification entry describes piston syringes under 21 CFR 880.5860, with Class II and a 510(k) submission type.^[5] That database entry is a starting point, not a classification determination for every product carrying U-100 on its label. Separately, FDA’s QMSR took effect on February 2, 2026 and incorporates ISO 13485:2016 by reference.^[6] A quality-system statement still does not establish the markings or performance of an individual REF.

A buyer’s documentation matrix may therefore include the legal manufacturer and site, product classification, applicable premarket record, establishment and listing information, UDI/GUDID information where applicable, current U.S. labeling, quality-system scope, sterile-product evidence, shelf-life information, change control and lot traceability. Applicability must be determined for the exact SKU, entities, market and transaction.

12. U.S. Inventory and Replenishment Questions

A U.S. warehouse can support faster replenishment, but location alone does not prove that the approved REF is available, released, within the required shelf-life window or traceable. Ask for a dated availability response for the exact SKU.

Tonmit’s U.S.-warehouse-supported fulfillment overview explains how availability, replenishment and domestic coordination should be reviewed as a supply program. For a broader vendor decision, use the framework to evaluate a wholesale insulin syringe supplier.

13. Copyable U-100 Insulin Syringe RFQ

Send the same field structure to every candidate. If a field is undecided, mark it “buyer review required” instead of allowing the supplier to silently choose.

U-100 INSULIN SYRINGE SPECIFICATION AND SUPPLY RFQ

Buyer / company:
Destination country and postal code:
Initial quantity / recurring demand:
Required delivery window:

REQUESTED DEVICE
Insulin scale: U-100
Capacity and maximum marking:
Graduation interval:
Needle gauge x exact length (mm / labeled inch value):
Fixed needle / verified safety / other approved configuration:
Primary sterile presentation and material statements:
Legal manufacturer / manufacturing site, if specified:
Manufacturer REF / brand SKU, if specified:
Label / artwork revision:
UDI / GTIN and applicable package level:

PACK AND DOCUMENTS
Pieces per primary pack:
Pieces per sales box:
Boxes per case:
Case dimensions and weight:
Current product specification and labels:
Applicable product-level regulatory and quality records:
Sterile-product and shelf-life documentation:
Lot/expiry format and traceability records:
Production-equivalent sample requirement:

QUOTE AND FULFILLMENT
Unit, box and case price:
MOQ and order multiple:
Freight basis / Incoterm / destination charges:
Current available REF, lot, expiry and allocable quantity:
Minimum remaining shelf life at receipt:
Production, dispatch and transit assumptions:
Partial-shipment and replenishment terms:
Private-label or artwork requirement, if any:

SUBSTITUTION
List every difference between the requested and offered configuration.
No change to controlled product or pack fields without prior written buyer approval.
Leave undecided fields marked 'buyer review required'; do not infer them from U-100 alone.

Do not include patient details or use this RFQ to calculate a dose.

14. Frequently Asked Questions

15. From “U-100 Syringes” to a Controlled Purchasing Specification

U-100 is simple to define but incomplete as a purchasing description. It identifies the insulin concentration system represented by the barrel scale; it does not establish capacity, graduation, needle, configuration, package, evidence or supply terms.

The useful procurement outcome is a controlled identity chain:

U-100 scale → capacity and maximum marking → graduation → needle and configuration → legal manufacturer and REF → label and package revision → lot and expiration → approved supply terms.

Once that chain is fixed, healthcare buyers can compare bulk U-100 insulin syringe supply, case economics, documentation and replenishment without allowing price or appearance to conceal a product difference.